Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is a Healthcare stock trading at $17.19 (as of 2026-08-21), with a market capitalization of $644.07M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
Contineum Therapeutics, a clinical stage biopharmaceutical company, develops novel oral small molecule therapies for neuroscience, inflammation, and immunology, including PIPE-791 (an LPA1R inhibitor for idiopathic pulmonary fibrosis and progressive multiple sclerosis) and PIPE-307 (an M1 selective inhibitor for depression and relapse), and it shows 0.0B of reported revenue in the latest quarter.
The profit model depends on how well PIPE-791 and PIPE-307 translate from early human pharmacology into later clinical success, with early development progress reflected in exposure and study design measures like Plasma Effective Concentration 50 at 24 Hours and the number of Healthy Volunteers.
Business quality (Weak): High unmet-need targeting and clear scientific focus, but investors have limited operating visibility because the company is clinical stage with no reported revenue in the latest quarter and deeply negative operating results.
| Price | $17.19 |
| Market Cap | $644.07M |
| Price / Book | 2.69 |
| Price / Sales | 69.19 |
| FCF Yield | -16.1% |
| Revenue (TTM) | $8.25M |
| Net Margin | -727.4% |
| Revenue Growth (YoY) | 37.5% |
| EPS Growth (YoY) | -82.5% |
| FCF Growth (YoY) | 78.0% |
| Altman Z-Score | 17.69 (safe) |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Top Institutional Holder | Jupiter Topco LLC ($44.77M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Carmine N. Stengone |
| Employees | 41 |
| Country | US |
| IPO Date | 2024-04-05 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.